Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Researchers are evaluating a new medicine called Risvutatug Rezetecan also known as GSK5764227 in participants worldwide who have advanced gastrointestinal cancers that cannot be surgically removed. This study focuses on participants who have already received prior treatment and aims to assess how well the medicine works, how safe it is, and how the body processes it. It is a Phase 1b2, multicenter, open-label trial sponsored by GlaxoSmithKline. Participants will receive Risvutatug Rezetecan alone or in combination with other treatments. Multiple dosing groups exist, including different doses tailored to colon, rectum, and pancreatic cancer cohorts. The study uses a randomized, parallel design to compare these groups. Treatments are given according to assigned doses, and the trial monitors participants for up to approximately 37 months to assess response and safety. During the study, participants will undergo regular assessments including scans, blood tests, vital signs, and electrocardiograms. Researchers will measure confirmed objective response rates up to about 22 months, and additional outcomes such as progression-free survival, duration of response, adverse events, and changes in clinical and laboratory parameters over about 37 months. Participants are monitored closely for safety and treatment effects throughout their involvement in the trial.